liveperson establish bullish three- five-year target
investor day reiter outperform rais pt
platform momentum continu addit catalyst
track toward high-end sizabl growth
color fundament focu call
pivot data eha may bring sickl cell patient
number ahead expect growth opportun continu
encourag
healthcar strength stabil nutrit segment
rais pt maintain outperform result
analyst certif import disclosur see
updatefocu nash file launch prepar
updat inspir optimist outlook develop
review meaning clinic valid anticip
review wood chop
manifest eha
first glanc
growth pain in-lin temper guidanc
first look modest miss weaker ebitda guidanc
larg guidanc conserv pend
product market initi maintain perform valuat
exce macro rebound management confid ibuy
strong demand servic offer test no-fe buyer
follow-up disappoint organ growth interout
synergi track lower pt
vg follow-up solid quarter busi growth increas
ye
reduc estim pt lower
mix quarter expect softer april increas skeptic
hotel revenu improv back half
quick read model continu take shape
quick read disappoint guid high-expect set-up
rais estim maintain outperform rate gener
cash-rais catalyst underscor valu proposit
fundament back track beat reiter guidanc
quarter better effici
tight quarter dividend cover expect continu
anoth solid quarter -- row
in-lin stabl quarter reiter outperform
liveperson establish bullish three- five-year target investor day reiter outperform rais pt
yesterday manag gave upbeat set present first investor day seven year held nyc found
manag updat convers commerc opportun product portfolio roadmap enterpris midmarket
go-to-market strategi ai-bot driven consum engag adopt pipelin momentum posit bottom line believ
well posit liveengag messag platform capit futur shift consum engag messag
channel think multipl growth lever busi pull drive potenti rare saa industri acceler growth profil
catalyz re-rat valuat multipl higher coincid improv growth profil reiter outperform rais pt
follow meet manag cfo vice-president ir key takeaway includ heel solid result manag
remain laser focus quickli transit busi model subscript driven one recent upward guidanc
subscript contribut total licens prior leav room upsid revis combin expand
platform recept custom base new exist healthi spend environmental provid support momentum view
opportun rel restrain competit environ provid long-term necessari fuel continu drive
toward revenu goal reiter outperform pt
platform momentum continu addit catalyst larger publish deal maintain outperform
increas price target maintain outperform rate report strong result ahead
street expect rais guidanc one-third smart tv sold us power oper system
make smart tv provid monet platform differ method scale undeni us
household grow y/i manag rais revenue/gp respect remov near-term concern two
lead ad-support partner pluto tv cheddar acquir larger compani price target assum platform gp
premium snap discount grow faster
track toward high-end sizabl growth expect
substanti out-performance remind pois demonstr sizabl growth margin expans via continu
solid busi condit modspac acquisit integr synergi primari driver includ sixth consecut quarter
double-digit y/i pro forma monthli rental rate growth modular-u segment revenu mix y/i adjust
ebitda expans via acquisit cost synergi adjust ebitda margin improv repres y/i pro
forma expans although indic portion adjust ebitda margin out-performance timing-rel caution
y/i expans would less pronounc increment confid seemingli conserv maintain
adjust ebitda y/i reiter outperform target
color fundament focu call
pivot data eha may bring sickl cell patient
wednesday report earn discuss recent progress manag follow pre-nda meet regul
manag expect complet roll nda submiss voxelotor put drug track potenti acceler approv
support applic compani plan present full pivot data phase studi eha june
base posit interim result expect registr dataset like hit primari endpoint possibl show increas separ
studi arm key secondari endpoint includ vaso-occlus crise voc potenti launch horizon suffici
cash support oper commerci reiter outperform rais pt previous
report net loss vs estim revenu vs estim pdufa date remain
unassign bivigam pa see approv juli earlier reflect review period view recent approv asceniv
formal produc facil nearli ident plasma fraction process key support thesi believ
share significantli undervalu busi prospect view current level attract entri ahead upcom newsflow
anticip revenu growth
net loss came less estim stage salesforc strategi steadili work toward
secur dsuvia inclus hospit formulari sinc product mid-februari launch reiter expect least
approv current account manag team expand earli previous indic earli commerci
progress regist uncertainti dsuvia launch trajectori peak sale potenti keep us sidelin pend
net loss line estimate phase solar trial cobomarsen mycosi fungoid activ recruit top-
line data expect encourag evid clinic activ atll support develop aggress malign remlarsen
phase trial keloid produc data develop topic ophthalm formul contempl follow support
observ corneal injuri model reiter outperform rate solar progress newsflow around compani
mirna-target pipelin gener
number ahead expect growth opportun continu encourag
number first quarter came ahead consensu vs consensu product segment came
model due client closur strength servic segment gener number ahead expect margin improv
sinfoniarx saa softwar revenue contribut prescribewel expect drive gm higher end target
year-end traction multipl product line encourag near-term opportun health plan commun pharmacist market
intern provid market continu evolv focu value-bas reimburs drive demand mtm solut
expect benefit reiter outperform target
healthcar strength stabil nutrit segment improv sentiment
report better expect number healthcar nutrit segment strong visit growth silversneak program
lift new subscrib prime program lift healthcar segment revenu offset attrit tv media spend begin
year produc strong result expect see continu focu drive silversneak enrol util nutrisystem post
much better expect result slow start year quarter see lift activ due time media spend
posit result quarter stabil nutrisystem segment increas confid cross-sel health plan improv
investor sentiment increas target reiter outperform
reiter outperform rate revis price target post busi updat rocklatan market
commerci live coverag launch expect compani may continu execut effect drive uptak among
prescrib well payer also note manag effort creat long-term sharehold valu includ proactiv strengthen
balanc sheet non-dilut fund activ seek pipelin expans opportun fund intern effort invest
ou expans believ savvi manag team may posit grow major global ophthalmolog player
next sever year
rais pt maintain outperform result
report result line estim revenu adjust net incom beat consensu beat
adjust ep due higher share repurchas quarter manag maintain overal guidanc indic anticip quarterli
variabl erwinaz defitelio expect increas sg spend come quarter sunosi solriamfetol launch note
strong earli vyxeo momentum eu await manag updat asparaginas program sunosi commerci strategi later
year maintain outperform rate slightli higher price target vs
updatefocu nash file launch prepar
report financi result updat key initi includ prepar commerci oca nash manag provid
insight quantit nash market research highlight import fibrosi improv endpoint us nda file
slightli acceler eu file plan investor focus nash littl concern sale pbc
roughli line expect us vs estim consensu ex-u sale
beat estim consensu ep estim consensu driven increas spend relat
nash prepar increas ocaliva net sale guidanc previous
ntec report ep roughli line consensu ntec provid busi updat identifi
potenti monet event us market opportun depend effect size pd patient ap-cd/ld
accord data readout demonstr reduct time compar rytari accord payer research
market potenti novarti partner program enter clinic believ ap-cd/ld pd significantli de-
risk follow recent pk data exhibit smoother pk profil tid dose vs ir-cd/ld view ntec ap platform technolog
attract wide-rang potenti partner look forward pd kol lunch event boston detail full report
report result roughli line expect includ ep match consensu ahead
estim andexxa revenu includ inventori stock fill specialti distribut channel andexxa
underli revenu close estim may miss consenu sinc clear figur includ stock
manag indic hospit order andexxa reorder rate reach increas hospit
end metric line estim publish hospital-bas andexxa sale forecast ask
sustain ad new hospit per quarter manag express confid rate detail report
updat inspir optimist outlook develop mileston
report ep vs estim consensu encourag recent progress
upcom catalyst includ enhanc pivot studi seladelpar pbc enrol expect complet fda
breakthrough therapi design btd grant seladelpar pbc post-urso poc studi seladelpar nash
complet enrol earli top-lin data expect end equiti rais support upcom psc develop view
seladelpar well-differenti asset seem suffici fund cash end reiter
outperform rate pt detail full report releas
review meaning clinic valid anticip
report financi result provid corpor updat mrna develop platform back compani
scienc day manag host call discuss updat pipelin progress well formal nomin new candid
addit new indic updat plan rsv nomin second gener product
ind file alreadi continu impress agil breadth develop platform look
forward upcom american societi clinic oncolog meet june oncolog portfolio receiv updat
updat model stay bullish
review wood chop
sarepta report financi result provid corpor updat progress quarter quarterli result
rel benign effect line estim exondi sale confer call heard ad color
competit pressur dmd gene therapi could remain investor mind initi readout june continu
believ work lay ahead gene therapi despit sarepta earli result look forward manag execut manufactur
initi remain focus execut across gene therapi pipelin well regulatori clariti registr
path forward stay neutral
manifest eha
report ep vs estim consensu encourag recent progress
upcom catalyst includ interim analysi manifest trial poster june eha oral june
addit data present interim data prostar present interim
prostar data show clinic activ combin either abirateron enzalutamid subset mcrpr
patient ind file follow-on inhibitor also expect suffici fund
cash end reiter outperform rate pt
first glanc
report adj ep top opco/street consensu adj result exclud afam/
acquisit cost relat closur reloc consolid impair charg beat vs model
larg driven tax rate admiss trend soften littl torrid pace particularli medicar cost control help
overcom top-lin pressur due tax-rat adjust cost control compani rais ep guidanc
result illustr consist execut nt goal attain ceo mark benjamin mark one year
anniversari essenti four consecut quarter better-than-expect result coupl recent imag divis sale
track auto spin-out indic compani posit momentum direct healthcar revenu
enterpris revenu divis becom pivot focu long-term context posit view addit
robert dahdah formerli cro apples-to-appl basi exceed revenu ep target rais
ep reiter revenu target continu oper reiter outperform pt
growth pain in-lin temper guidanc lower pt
common truth young growth compani certain stage feel temporari grow pain whether need find shine
path growth opportun oper expens need tackl intern sale execut issu use impv
note believ applic wherea line lower guidanc rais concern chang market
dynam demand trend believ hit execut bump onu proof manag allevi concern
iga market still grow see displac greenfield opportun take advantag current weak
valuat suggest trough level
first look modest miss weaker ebitda guidanc fy unchang
angi report revenu street estim repres y/i growth acceler vs y/i pro forma base
ex felix marketplac revenu y/i vs y/i north america revenu y/i vs europ y/i ex
fx vs y/i marketplac sp y/i vs y/i opco/street estim marketplac sr
opco/street grow y/i vs ebitda opco/street lower margin
revenu guid acceler bit pro forma pace suggest modest pick-up ebitda guid
opco/street anticip invest pre-pric servic warranti demand transact bring job sp
management maintain guidanc share buy-back plan author unus confer call schedul et
deliv strong result provid fy guidanc line street view alreadi reflect stock
sale gms/revenu line opco/street ebitda opco/street market pullback manag
rais low-end fy guidanc alreadi reflect street estim investor focu market drive return/new custom
benefit big data migrat improv convers stock like range-bound unless revenu growth acceler view maintain
larg guidanc conserv pend product market initi maintain perform
maintain perform rate valuat even though continu report strong result guidanc look conserv
expect revenu growth slow y/i ex fx vs y/i mostli sub y/i na y/i y/
tinder ad sub fy guidanc conserv unchang slowdown could off-set
new product hing reach download minim subscript match com updat could benefit tinder/snap stori
integr announc expand commentari goal expans india/asia revenu today share remain
expensiveon limit floatat sale grow compound-annual-growth-rate vs subscript internet peer similar growth
exce macro rebound management confid ibuy strong demand servic offer test no-
rais price target stronger result management outlook improv macro trend increas confid
ibuy servic offer real estat revenu y/i vs estim acceler
market share increas bp y/i properti revenu flat q/q ahead management increas confid offer
unveil redfin direct allow buyer make offer redfin-list home without agent catch would
two-sid discount brokerag model industri trade revenu compound-annual-growth-rate vs peer valu
growth maintain outperform rate
cloud
follow-up disappoint organ growth interout synergi track lower pt
organ revenu growth dip neg anem growth last quarter time delay issu attribut migrat
legaci interout system proprietari client manag databas delay provis posit manag saw strong
margin expans weak growth evid interout access point synergi realiz manag make progress
toward next financi object futur acquisit could catalyst revenu adj ebitda
need focu execut integr go-to-market perspect confid achiev
full interout synergi time lower pt
cloud
vg follow-up solid quarter busi growth increas ye
vg invest onevonag cloud platform reson larger custom result acceler busi growth
two main busi product categori applic api platform leverag network infrastructur underli code
help vg creat uniqu servic uniqu go-to-market posit nexmo grew y/i nexmo see grow momentum
ad custom ever improv servic go-to-market strategi posit declin consum busi
revenu mix creat less drag consolid growth result expect consolid revenu
growth acceler
cloud
reduc estim pt lower ebitda
boingo result continu lumpi compani transit new busi lose legaci amex/retail account impact ny
port author contract extens report revenu growth vs estim adjust reamort da
revenu grew unadjust normal port author contract retail/advertis revenu weak think
stabil boingo ad three da contract get look deploy venu back half howev
reduc price target lower cash ebitda quarter estim higher debt load
mix quarter expect softer april increas skeptic hotel revenu improv back half
commentari softer april hotel meta auction trend caus higher skeptic platform segment abil gener sustain
profit growth complet market optim initi drove anoth solid ebitda quarter y/i ex-fx softer auction
owe slower intern macro base stabl bid lower demand howev factor competit could impact
growth base player express limit shift macro dynam sinc februari increas disclosur three segment improv
